Patents by Inventor Christopher M. Counter

Christopher M. Counter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8927598
    Abstract: Oncogenic Ras-driven cancer is treated with agent by interrupting pathway comprising activation of Akt by oncogenic Ras, activated Akt causing phosphorylation of eNOS at S1177 site of eNOS to provide activated eNOS in cancer cells and activated eNOS causing activation of wildtype Ras by nitrosylation thereof at C118 to provide GTP-bound activated wildtype H and N Ras. L-NAME can be orally administered to interrupt this pathway. Wortmannin can be administered intravenously to interrupt this pathway. Novel siRNAs are disclosed useful to interrupt said pathway.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: January 6, 2015
    Assignee: Duke University
    Inventors: Christopher M. Counter, Kian-Huat Lim, Brooke B. Ancrile, David F. Kashatus
  • Patent number: 8771982
    Abstract: The present invention relates, in general, to telomeres, and, in particular, to a method or effecting telomere elongation in mammalian cells. The invention further relates to a protein suitable for use in such a method and to nucleic acid sequences encoding same.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: July 8, 2014
    Assignee: Duke University
    Inventors: Christopher M. Counter, Blaine N. Armbruster
  • Patent number: 7943378
    Abstract: The present invention relates, in general, to tissue engineering and, in particular, to a method of extending the lifespan of cells suitable for use in vascular engineering.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: May 17, 2011
    Assignee: Duke University
    Inventors: Laura E. Niklason, J. Andrew McKee, Christopher M. Counter
  • Publication number: 20110003887
    Abstract: Oncogenic Ras-driven cancer is treated with agent by interrupting pathway comprising activation of Akt by oncogenic Ras, activated Akt causing phosphorylation of eNOS at S1177 site of eNOS to provide activated eNOS in cancer cells and activated eNOS causing activation of wildtype Ras by nitrosylation thereof at C118 to provide GTP-bound activated wildtype H and N Ras. L-NAME can be orally administered to interrupt this pathway. Wortmannin can be administered intravenously to interrupt this pathway. Novel siRNAs are disclosed useful to interrupt said pathway.
    Type: Application
    Filed: January 9, 2009
    Publication date: January 6, 2011
    Applicant: Duke University
    Inventors: Christopher M. Counter, Kian-Huat Lim, Brooke Ancrile, David F Kashatus
  • Publication number: 20030235562
    Abstract: The present invention relates, in general, to tissue engineering and, in particular, to a method of extending the lifespan of cells suitable for use in vascular engineering.
    Type: Application
    Filed: March 17, 2003
    Publication date: December 25, 2003
    Inventors: Laura E. Niklason, J. Andrew McKee, Christopher M. Counter
  • Patent number: 5840490
    Abstract: Methods for detecting hematologic and colorectal malignancies are provided comprising: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the presence of telomerase activity with the presence of cancer cells. A method for staging leukemia is also provided comprising analyzing a blood or bone marrow sample for telomerase activity, correlating the activity with a standard level of telomerase activity, and correlating a low telomerase activity with early stage leukemia.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignee: McMaster University
    Inventors: Silvia Bacchetti, Christopher M. Counter, Brian Leber, Calvin Bruce Harley